Icon Public Limited (NASDAQ:ICLR) stock and Charles River Laboratories (NYSE:CRL) stock trade lower as Goldman Sachs ...

Investing.com — 周五，高盛调整了对ICON plc（NASDAQ:ICLR）的立场，将该股评级从"买入"下调至"中性"，并将目标价从250.00美元降至200.00美元。这一评级变化是因为该公司调整了对这家临床研究组织（CRO）行业知名企业近期前景的看法。根据 InvestingPro ...

Icon has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes Icon the first CRO to completely integrate this technology into its workflows. The ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research ...

Goldman Sachs downgraded Icon (ICLR) to Neutral from Buy with a price target of $200, down from $250. While the firm continues to believe that ...

ICON plc (NASDAQ:ICLR), a leading global Contract Research Organization (CRO) with a market capitalization of $16.38 billion, has been navigating a complex market environment characterized by ...

New York, New York-- (Newsfile Corp. - March 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 ...

ICON plc (NASDAQ:ICLR), a leading global Contract Research Organization (CRO) with a market capitalization of $16.38 billion, has been navigating a complex market environment characterized by shifting ...

We came across a bullish thesis on ICON Public Limited Company (ICLR) on Substack by Oliver | MMMT Wealth. In this article, ...